Targeting cancer with kinase inhibitors

Stefan Gross, Rami Rahal, Nicolas Stransky, Christoph Lengauer, Klaus P. Hoeflich

Research output: Contribution to journalArticle

Abstract

Kinase inhibitors have played an increasingly prominent role in the treatment of cancer and other diseases. Currently, more than 25 oncology drugs that target kinases have been approved, and numerous additional therapeutics are in various stages of clinical evaluation. In this Review, we provide an in-depth analysis of activation mechanisms for kinases in cancer, highlight recent successes in drug discovery, and demonstrate the clinical impact of selective kinase inhibitors. We also describe the substantial progress that has been made in designing next-generation inhibitors to circumvent on-target resistance mechanisms, as well as ongoing strategies for combining kinase inhibitors in the clinic. Last, there are numerous prospects for the discovery of novel kinase targets, and we explore cancer immunotherapy as a new and promising research area for studying kinase biology.

Original languageEnglish (US)
Pages (from-to)1780-1789
Number of pages10
JournalJournal of Clinical Investigation
Volume125
Issue number5
DOIs
StatePublished - May 1 2015
Externally publishedYes

Fingerprint

Phosphotransferases
Neoplasms
Activation Analysis
Drug Discovery
Immunotherapy
Therapeutics
Research
Pharmaceutical Preparations

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Gross, S., Rahal, R., Stransky, N., Lengauer, C., & Hoeflich, K. P. (2015). Targeting cancer with kinase inhibitors. Journal of Clinical Investigation, 125(5), 1780-1789. https://doi.org/10.1172/JCI76094

Targeting cancer with kinase inhibitors. / Gross, Stefan; Rahal, Rami; Stransky, Nicolas; Lengauer, Christoph; Hoeflich, Klaus P.

In: Journal of Clinical Investigation, Vol. 125, No. 5, 01.05.2015, p. 1780-1789.

Research output: Contribution to journalArticle

Gross, S, Rahal, R, Stransky, N, Lengauer, C & Hoeflich, KP 2015, 'Targeting cancer with kinase inhibitors', Journal of Clinical Investigation, vol. 125, no. 5, pp. 1780-1789. https://doi.org/10.1172/JCI76094
Gross S, Rahal R, Stransky N, Lengauer C, Hoeflich KP. Targeting cancer with kinase inhibitors. Journal of Clinical Investigation. 2015 May 1;125(5):1780-1789. https://doi.org/10.1172/JCI76094
Gross, Stefan ; Rahal, Rami ; Stransky, Nicolas ; Lengauer, Christoph ; Hoeflich, Klaus P. / Targeting cancer with kinase inhibitors. In: Journal of Clinical Investigation. 2015 ; Vol. 125, No. 5. pp. 1780-1789.
@article{f96227264b8241acb3ba12268293a81a,
title = "Targeting cancer with kinase inhibitors",
abstract = "Kinase inhibitors have played an increasingly prominent role in the treatment of cancer and other diseases. Currently, more than 25 oncology drugs that target kinases have been approved, and numerous additional therapeutics are in various stages of clinical evaluation. In this Review, we provide an in-depth analysis of activation mechanisms for kinases in cancer, highlight recent successes in drug discovery, and demonstrate the clinical impact of selective kinase inhibitors. We also describe the substantial progress that has been made in designing next-generation inhibitors to circumvent on-target resistance mechanisms, as well as ongoing strategies for combining kinase inhibitors in the clinic. Last, there are numerous prospects for the discovery of novel kinase targets, and we explore cancer immunotherapy as a new and promising research area for studying kinase biology.",
author = "Stefan Gross and Rami Rahal and Nicolas Stransky and Christoph Lengauer and Hoeflich, {Klaus P.}",
year = "2015",
month = "5",
day = "1",
doi = "10.1172/JCI76094",
language = "English (US)",
volume = "125",
pages = "1780--1789",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "5",

}

TY - JOUR

T1 - Targeting cancer with kinase inhibitors

AU - Gross, Stefan

AU - Rahal, Rami

AU - Stransky, Nicolas

AU - Lengauer, Christoph

AU - Hoeflich, Klaus P.

PY - 2015/5/1

Y1 - 2015/5/1

N2 - Kinase inhibitors have played an increasingly prominent role in the treatment of cancer and other diseases. Currently, more than 25 oncology drugs that target kinases have been approved, and numerous additional therapeutics are in various stages of clinical evaluation. In this Review, we provide an in-depth analysis of activation mechanisms for kinases in cancer, highlight recent successes in drug discovery, and demonstrate the clinical impact of selective kinase inhibitors. We also describe the substantial progress that has been made in designing next-generation inhibitors to circumvent on-target resistance mechanisms, as well as ongoing strategies for combining kinase inhibitors in the clinic. Last, there are numerous prospects for the discovery of novel kinase targets, and we explore cancer immunotherapy as a new and promising research area for studying kinase biology.

AB - Kinase inhibitors have played an increasingly prominent role in the treatment of cancer and other diseases. Currently, more than 25 oncology drugs that target kinases have been approved, and numerous additional therapeutics are in various stages of clinical evaluation. In this Review, we provide an in-depth analysis of activation mechanisms for kinases in cancer, highlight recent successes in drug discovery, and demonstrate the clinical impact of selective kinase inhibitors. We also describe the substantial progress that has been made in designing next-generation inhibitors to circumvent on-target resistance mechanisms, as well as ongoing strategies for combining kinase inhibitors in the clinic. Last, there are numerous prospects for the discovery of novel kinase targets, and we explore cancer immunotherapy as a new and promising research area for studying kinase biology.

UR - http://www.scopus.com/inward/record.url?scp=84929012081&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84929012081&partnerID=8YFLogxK

U2 - 10.1172/JCI76094

DO - 10.1172/JCI76094

M3 - Article

VL - 125

SP - 1780

EP - 1789

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 5

ER -